Released Feb 24, 2026, after the close
10-K filed Mar 16, 2026, 75 days after period end · 0001193125-26-108326
Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$23.80M$23.80M derived+2,573.6% vs Q4 2024+21.7% vs Q3 2025
Net Income$19.28M$19.28M derivedN/M vs Q4 2024N/M vs Q3 2025
EPS, diluted—Not derived. Share counts vary by quarter.
Gross Profitderived$11,382,000N/M
Operating Incomederived-$24,644,000N/M
Operating Cash Flowderived-$1,190,000N/M
Free Cash Flowderived-$1,666,000N/M
Margins · derived
Gross margin47.8%+250.6 pt vs Q4 2024
Operating margin-103.6%+1058.6 pt vs Q4 2024
Net margin81.0%+3909.4 pt vs Q4 2024
What the release said
The release
Same quarter
| Metric | Q4 2025dderived from reported figures | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures |
|---|---|---|---|---|
| Revenue | $23.80M | $890.00K | $28.19M | $27.02M |
| Net Income | $19.28M | -$34.07M | -$19.78M | -$20.85M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Standard Biotools Inc. · CIK 1162194 · Engraved from SEC EDGAR